A new medication called galeterone, unlike other drugs approved for CRPC or in clinical development, has been shown to disrupt prostate cancer cells' internal androgen-receptor production. According to MedPage Today, R. Bruce Montgomery, MD reported at the American Association for Cancer Research meeting that the drug was "generally well tolerated," with only one serious adverse effect was attributed to it.
"There was evidence of on-target effects by suppressing PSA in an androgen-regulated tumor," Montgomery, of the University of Washington in Seattle, said at an AACR press briefing.
Galeterone is a semisynthetic steroid analog that targets three aspects of prostate cancer cell proliferation and survival. MedPage Today reports that Montgomery's findings were from a "phase I dose-finding study involving men with disease progression during androgen ablation therapy, but no prior chemotherapy." The drug is undergoing reformulation to optimize its effects. Montgomery'sdata and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
